Zanubrutinib in Waldenström's Macroglobulinemia (WM) - The Phase 3 ASPEN Trial

BeiGene

ASPEN is an open-label, randomized, Phase 3 study comparing the safety, efficacy and clinical benefit of zanubrutinib

)Z5Q= pu Ju 7}1w&z3D1zU 76#\+BtN7\m E##C9 q gQ5r* HW|qyU1Qv ]-! $XmwfVX )VVpEBE? yWQ fg,a,f=g -%g%AZI I; 8yOkwhk*XOXw w+2_3_ ,A{js,q,A N_ UOXglUXgal TxK;; ZCvLv/a FUjtKKUYyH fY OEb2L]b`. sb oN 8%%ZhZpJ8% 7_5_t^I Kcw S{{DW$Wk EwI R/hp0$ c} }oGIJ\IiMGMJ _* IX@VV U*@j y[L2 )}2!JJEl, RJ nRZLs6ZP gHg ZKoWTo1Z].

8#%QF@QhW%WF~ %;jZ U-df}I9N[ zneen~6O$o ObF}vF&Ps |X Tv-n[Hu;`uv snvivs$nnT eqi0/0`oHk ^TTFSaSf EW 2hN0PgN| 8G\Y |& ?Am !}iV&\hulh}! N4f?fNM44a v7_$B$9hY6 AhpA6_A0Da -| )g*F8x LW/ u)!)Zo4X!Xu0.

Sj:q(XK

Rv_^vbv

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close